Ethics Challenges and Responses

>> Sunday, February 20, 2011

Challenging Cheating Testing assumptions about academic dishonesty at Harvard


Conversation with Gary Kaplan, CEO, Virginia Mason Medical Center
For those who enjoyed hearing from GHS CEO Mike Riordan in the last issue, and have a continuing interest in the issues around health care reform, we share the following article featured in Ethix, another online newsletter. It is part two of an Ethix special edition on health care.
http://ethix.org/2011/01/11/dr-gary-s-kaplan-determined-steps-to-transformation

**************************************************************************



Lessons from the Bacteria: How Good Culture Trumps Bad Leadership
December 6 commentary from Rushworth M. Kidder

**************************************************************************

The Profits if Nonprofit: The surprising results when drug development and altruism collide
Volume 25 | Issue 1 | Page 54   Date: 2011-01-01
The Profits of Nonprofit - The Scientist - Magazine of the Life Sciences http://www.the-scientist.com/article/display/57891/#ixzz1BJJAgJ68

**************************************************************************
Four-Way Test a Good Barometer
Thanks to George West for his mention of Linda G talking about Rotary's Four-Way Test in a presentation on the economics of integrity at the Rotary Club of Anderson meeting. His piece was eerily prophetic of the tragedy in Tucson that occurred later that day, January 8th.
http://www.independentmail.com/news/2011/jan/08/four-way-test-good-barometer/

***************************************************************************
Supreme Court to Hear Arguments in Zicam CaseThe Arizona Republic (1/10, Alltucker) reports that a "Scottsdale-based company that sells Zicam cold and flu products will argue a case today before the U.S. Supreme Court that could shape what drug makers, medical companies and other businesses tell investors about their products." The article adds that the "case centers on whether publicly traded Matrixx Initiatives violated securities laws when it didn't tell investors that some consumers complained that they lost their sense of smell after using Zicam Cold Remedy nasal spray and gel swabs." Notably, drug makers supporting Matrixx Initiatives are "arguing that widespread disclosure of medical complaints from people who take drugs or use medical devices would confuse investors and consumers."
http://www.azcentral.com/business/articles/2011/01/09/20110109supreme-court-hear-zicam-case-0110.html

***************************************************************************


0 comments:

Enjoyed this Newsletter? Like our Work?

Join the Rutland Ethics Alliance and support us in what we do!



  © Free Blogger Templates Wild Birds by Ourblogtemplates.com 2008

Back to TOP